Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.40 |
| ▸ | MGLL | Q99685 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15597354 | 0.88 | FAAH (0.46) | FAAHMGLLBCHEMEN1KMT2A | |
| SCHEMBL13941537 | 0.83 | FAAH (0.51) | FAAHMGLLBCHE | |
| SCHEMBL23818373 | 0.82 | FAAH (0.51) | FAAHMGLLBCHEMEN1KMT2A | |
| SCHEMBL20811742 | 0.81 | FAAH (0.44) | FAAHMGLLBCHE | |
| SCHEMBL21207962 | 0.79 | FAAH (0.46) | FAAHMGLLBCHEMEN1KMT2A | |
| SCHEMBL24529020 | 0.77 | FAAH (0.37) | FAAHMGLLBCHEMEN1KMT2A | |
| SCHEMBL21697211 | 0.75 | F7 (0.42) | FAAHMGLLBCHE | |
| SCHEMBL13431057 | 0.74 | PLK4 (0.57) | FAAHMGLLBCHE | |
| SCHEMBL13160507 | 0.74 | PLK4 (0.57) | FAAHMGLLBCHE | |
| SCHEMBL13941402 | 0.74 | PLK4 (0.57) | FAAHMGLLBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179522-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179522-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | PSMG3, MYCBP, DBN1 | FAAH 3986/4885MGLL 3387/4885BCHE 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.